Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

This study is testing whether a personalized mRNA vaccine — similar in concept to COVID mRNA vaccines but designed to target your specific cancer — combined with a PD-1 immune checkpoint drug, can help prevent pancreatic cancer from coming back after surgery. **You may be eligible if...** - You are 18 or older and have had surgery to remove pancreatic cancer in the past 1–3 months - Your cancer has been confirmed by pathology (tissue testing) - Genetic testing of your tumor found at least one target (neoantigen) for the vaccine - Your doctor feels you cannot tolerate standard chemotherapy (ECOG score ≥ 2) - Your HLA genes (immune system markers) are intact **You may NOT be eligible if...** - You received chemotherapy or other cancer treatments in the 4 weeks before enrolling - You have a history of a serious lung condition like pulmonary fibrosis - You have HIV, immune deficiency, or a history of severe allergic reactions to vaccines or immunotherapy drugs - Your doctor believes you are unsuitable for other reasons Talk to your doctor to see if this trial is right for you.